Myeloproliferative neoplasms: A decade of discoveries and treatment advances

American Journal of Hematology

Volumn 91, Issue 1, 2016, Pages 50-58

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLPHENYLHYDRAZINE; ACETYLSALICYLIC ACID; ANDROGEN; ARSENIC TRIOXIDE; BUSULFAN; CALRETICULIN; CHLORAMBUCIL; CHLORMETHINE; DANAZOL; DAPSONE; FEDRATINIB; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE INHIBITOR; LEAD ACETATE; LENALIDOMIDE; MELPHALAN; MERCAPTOPURINE; MOMELOTINIB; PHOSPHORUS 32; PIPOBROMAN; POMALIDOMIDE; PREDNISONE; PYRIMETHAMINE; RUXOLITINIB; STAT PROTEIN; THALIDOMIDE; TRETAMINE; UNINDEXED DRUG; URAMUSTINE; JAK2 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CORRELATIONAL STUDY; ERYTHROCYTOSIS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INVESTIGATIVE PROCEDURES; LEUKEMIA VIRUS; LEUKOCYTOSIS; MEDICAL INFORMATION; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; ONCOGENE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION; ANTAGONISTS AND INHIBITORS; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; STEM CELL TRANSPLANTATION; THROMBOCYTHEMIA, ESSENTIAL;

HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS; STEM CELL TRANSPLANTATION; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84954285121     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24221     Document Type: Article

References (152)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375.
2. Bennett JH. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the Blood. Edinburgh Med Surg J 1845;64:413-423.
3. Heuck G. Zwei Falle von Leukamie mit eigenthumlichem Blut- resp. Knochenmarksbefund (Two cases of leukemia with peculiar blood and bone marrow findings, respectively). Arch Pathol Anat Physiol Virchows 1879;78:475-496.
4. Vaquez H. Sur une forme speciale de cyanose s'accompanant d'hyperglobulie excessive et peristente (On a special form of cyanosis accompanied by excessive and persistent erythrocytosis). Compt Rend Soc De Biol and Suppl Note Bull Et Mem Soc Med D'hop De Paris 3 ser 1895;12: 60;1892;4:384-388.
5. Osler W. Chronic cyanosis, with polycythemia and enlarged spleen: A new clinical entity. Am J Med Sci 1903;126:187-201.
6. Osler W. A clinical lecture on erythraemia (polycythaemia with cyanosis, maladie de Vaquez). Lancet 1908;1:143-146.
7. Epstein E, Goedel A. Hamorrhagische thrombozythamie bei vascularer schrumpfmilz (Hemorrhagic thrombocythemia with a vascular, sclerotic spleen). Virch Arch Pathol Anat Histopathol 1934;293:233-248.
8. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967;58:1468-1471.
9. Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: Stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913-916.
10. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189-194.
11. Fialkow PJ, Faguet GB, Jacobson RJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916-919.
12. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
13. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960;132:1497.
14. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293.
15. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-554.
16. Stam K, Heisterkamp N, Grosveld G, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 1985;313:1429-1433.
17. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233:212-214.
18. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-830.
19. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
21. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
22. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
23. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
24. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
25. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
26. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
27. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
28. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631-635.
29. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006;20:350-353.
30. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-1849.
31. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005;366:1945-1953.
32. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-213.
33. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-2284.
34. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol 2005;131:320-328.
35. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507-2513. quiz 2615.
36. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468.
37. Broseus J, Park JH, Carillo S, et al. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014;124:3964-3966.
38. Pardanani A, Lasho TL, Finke CM, et al. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol 2011;86:701-702.
39. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. Blood 2015.
40. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-5133. quiz 5252.
41. Tefferi A, Thiele J, Vannucchi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28:1407-1413.
42. Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol 2014;89:E121-E124.
43. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs. type 2 calreticulin mutations in primary myelofibrosis: Differences in phenotype and prognostic impact. Leukemia 2014;28:1568-1570.
44. Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014;124:2465-2466.
45. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 2015;372:601-612.
46. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123-133.
47. Marty C, Harini N, Pecquet C, et al. Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis. Blood 2014;124:157-157.
48. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014;123:2220-2228.
49. Chen E, Schneider RK, Breyfogle LJ, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice combine to promote disease progression in myeloproliferative neoplasms. Blood 2015;125:327-335.
50. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014;111:E5401-E5410.
51. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-1869.
52. Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2014;28:431-433.
53. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010;24:1713-1718.
54. Barbui T, Thiele J, Vannucchi AM, et al. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 2015;5:e337.
55. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): Results of an international study. Am J Hematol 2014;89:52-54.
56. Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89:199-202.
57. Barbui T, Thiele J, Carobbio A, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol 2014;89:588-590.
58. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010;85:62-69.
59. Madelung AB, Bondo H, Stamp I, et al. World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience. Am J Hematol 2013;88:1012-1016.
60. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-438.
61. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 2013;27:1874-1881.
62. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-1579.
63. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012;120:1197-1201.
64. Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014;28:2300-2303.
65. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol Off J Am Soc Clin Oncol 2011;29:3179-3184.
66. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for myelofibrosis research and treatment. Blood 2009;113:2895-2901.
67. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-1708.
68. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-397.
69. Hussein K, Pardanani AD, Van Dyke DL, et al. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010;115:496-499.
70. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2011;25:82-88.
71. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2009;85:14-17.
72. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of international prognostic scoring system and dynamic international prognostic scoring system. Haematologica 2011;96:167-170.
73. Patnaik MM, Caramazza D, Gangat N, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010;84:105-108.
74. Vaidya R, Caramazza D, Begna KH, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood 2011;117:5612-5615.
75. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010;24:105-109.
76. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756-761.
77. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-1483.
78. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients. Leukemia 2014;28:1804-1810.
79. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol Off J Am Soc Clin Oncol 2011;29:1356-1363.
80. Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:1087-1094.
81. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients. Leukemia 2014;28:1494-1500.
82. Wasserman LR. Polycythemia Vera Study Group: A historical perspective. Semin Hematol 1986;23:183-187.
83. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;50:114-124.
84. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
85. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
86. Ludin M. Ein betrag zur kentniss der symptmologie und therapie der primaren polycythemie. Z Klin Med 1917;84:460-476.
87. Eppinger H, Kloss K. Zur Therapie der Polyzythaemie. Therap Monatshefte 1918;32:322-326.
88. Forkner CE, Scott TFM, Wu SC. Treatment of polycythemia vera (erythremia) with a solution of potassium arsenite. Arch Intern Med 1933;51:616-629.
89. Lawrence JH. Nuclear physics and therapy: Preliminary report on a new method for the treatment of leukemia and polycythemia vera. Radiology 1940;35:51-60.
90. Falconer EH. The treatment of polycythemia vera with lead compunds. Am J Med 1942;203:856-857.
91. Shullenberger CC, Watkins CH. Effects of nitrogen mustard on the bone marrow in polycythemia vera. Ann Intern Med 1950;33:841-853.
92. Rosenthal N, Rosenthal RL. Treatment of polycythemia vera with triethylene melamine: Summary of thirtty cases. Arch Intern Med 1952;90:379.
93. Isaacs R. Treatment of polycythemia vera with daraprim. J Am Med Assoc 1954;156:1491-1493.
94. Wald N, Hoshino T, Sears ME. Therapy of polycythemia vera with myleran. Blood 1958;13:757-762.
95. Shullenberger CC. Long-range treatment of polycythemia vera with 6-mercaptopurine. Cancer Chemother Rep 1962;16:251-252.
96. Bond WH. Evaluation of compund 8103 Abbott (N, N' bis (bromopropionyl) piperazine) in the treatment of polycythemia rubra vera. Proc Am Assoc Cancer Res 1962;3:306.
97. Perkins J, Israuels MC, Wilkinson JF. Polycythaemia Vera: Clinical studies on a series of 127 patients managed without radiation therapy. Q J Med 1964;33:499-518.
98. Varela JE, Kremenchuzky S, Fraga A, et al. Evaluation of haemopoiesis and comparative study of 32P and chlorambucil therapy by means of radiotracers in polycythemia vera. Miner Nucl 1965;9:275-280.
99. Pengelly CD. Reduction of haematocrit and red-blood-cell volume in patients with polycythaemia secondary to hypoxic lung disease by dapsone and pyrimethamine. Lancet 1966;2:1381-1386.
100. West WO, Ruff JD, Yarboro JW. Response of polycythemia to treatment with a new agent: Hydroxyurea (abstract). Ann Intern Med 1970;72:795.
101. Logue GL, Gutterman JU, McGinn TG, et al. Melphalan therapy of polycythemia vera. Blood 1970;36:70-86.
102. Osler W. Chronic cyanotic polycythemia with enlarged spleen. Br Med J 1904;1.
103. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962;172:513-523.
104. Berk PD, Wasserman LR, Fruchtman SM, et al. Treatment of polycythemia vera: A summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, editors. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: W.B. Saunders; 1995. pp 166-194.
105. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety-A polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17-23.
106. Tefferi A, Pardanani A. Myeloproliferative neoplasms: A contemporary review. JAMA Oncol 2015;1:97-105.
107. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT/ELN international working group. Leukemia 2015.
108. Barbui Tea. Revision of IPSET thrombosis. Blood Cancer J, in press.
109. Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014;124:3021-3023.
110. Dillinger JG, Sideris G, Henry P, et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res 2012;129:91-94.
111. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemostasis 2007;33:313-320.
112. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:162-173.
113. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol 1986;23:132-143.
114. Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29:3907-3913.
115. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
116. Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 2014;93:2037-2043.
117. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006;107:451-458.
118. Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 2014;371:188-189.
119. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-3072.
120. Kuriakose ET, Gjoni S, Wang YL, et al. JAK2V617F allele burden is reduced by busulfan therapy: A new observation using an old drug. Haematologica 2013;98:e135-e137.
121. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372:426-435.
122. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis? Blood 2013;122:3843-3844.
123. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: Clarifying facts from myths. Blood 2012;119:2721-2730.
124. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-367.
125. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol 2010;89:1233-1237.
126. Silverstein MN. Agnogenic Myeloid Metaplasia. Acton Mass: Publishing Science Group; 1975. pp 126.
127. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007;13:377-383.
128. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288-296.
129. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006;106:1974-1984.
130. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.
131. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-1164.
132. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-4766.
133. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:915-925.
134. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-4569.
135. Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012;87:66-68.
136. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301-304.
137. Tefferi A, Passamonti F, Barbui T, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence. Blood 2013;122.
138. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
139. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
140. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365:1455-1457.
141. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053.
142. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1:643-651.
143. Pardanani A, Tefferi A, Jamieson C, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 2015;5:e335.
144. Abdelrahman RA, Begna KH, Al-Kali A, et al. Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol 2015;169:77-80.
145. Pardanani A, Abdelrahman RA, Finke C, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia 2015;29:741-744.
146. Abdelrahman RA, Begna KH, Al-Kali A, et al. Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia 2015;29:498-500.
147. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-1327.
148. Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-1445.
149. Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 2015;125:2649-2655.
150. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med 2015;373:920-928.
151. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015;373:908-919.
152. Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 2015;125:3347-3350. quiz 3364.